What I have: orforglipron · two weeks.
I am trying to build something sustainable rather than something thorough that I will abandon.
I have already decided the broad direction; this is about the specifics.
What would you do, and what would make you change course?
2 weeks is 14 days: 2 weekly administrations, and 0.5 four-week dose steps. Two draws fit inside that span honestly — baseline before the first dose, one repeat — plus a written trigger for anything extra. A third is a budget rather than a plan at 2 weeks. The constraint is that the markers worth drawing move more slowly than 14 days. An HbA1c integrates roughly the preceding ninety days, so a repeat at day 14 is still about 84 per cent pre-treatment blood and mostly reports where you started. Lipids and hepatic enzymes settle faster and are worth the repeat at 14 days. A renal panel earns its place at baseline specifically so that an early eGFR change has something to be a change from. Fix the repeat date at the start, in writing. A monitoring plan decided after a result arrives is not a plan, and nothing here is medical advice.
Standardise the conditions — same time of day, same fasting state, same laboratory — or you are measuring the conditions rather than yourself.
Same laboratory, same method, same time of day, same fasting state. Between-laboratory differences on several common analytes are larger than the changes people are trying to detect.
| Trial | Agent | n | Duration | Primary result |
|---|---|---|---|---|
| STEP 1 | Semaglutide 2.4 mg | 1,961 | 68 wk | −14.9 % vs −2.4 % weight |
| STEP 2 | Semaglutide 2.4 mg, T2DM | 1,210 | 68 wk | −9.6 % vs −3.4 % weight |
| SURMOUNT-1 | Tirzepatide 5/10/15 mg | 2,539 | 72 wk | −15 / −19 / −21 % weight |
| SURMOUNT-4 | Tirzepatide, withdrawal | 670 | 88 wk | Continued loss vs substantial regain |
| SELECT | Semaglutide 2.4 mg | 17,604 | ~40 mo | MACE HR 0.80 (0.72–0.90) |
| FLOW | Semaglutide 1.0 mg, CKD | 3,533 | ~3.4 yr | Renal composite reduced; stopped early |
| SURMOUNT-OSA | Tirzepatide, OSA | 469 | 52 wk | AHI reduced with and without PAP |
Repeat before you react. A single abnormal value has a substantial probability of being within the combined biological and analytical variation of a normal one.
External quality assurance schemes document between-laboratory differences on common analytes that routinely exceed the size of clinically interesting changes.
Nothing here is medical advice. If something is out of range and you do not know why, that is a consultation rather than a research project.
Same laboratory, same time, same fasting state, or the comparison is not a comparison.
Aggregated, published test results and vendor ratings built from submitted batches. Methodology stated, dataset browsable, no listing fees.
Browse resultsAnswering this needs to distinguish screening from monitoring. A screening panel looks for the unexpected; a monitoring panel tracks something you already have a reason to watch.
Delta checks — comparing against your own previous value — are far more sensitive than comparing against a population interval, which is the argument for keeping a series rather than a snapshot.
To be exact about it, haemolysis in the sample raises potassium and several enzymes spuriously. If a result is bizarre, ask whether the sample was flagged before building a theory on it.
Pre-analytical factors — posture, tourniquet time, fasting, sample handling — are the largest source of error in routine biochemistry, well ahead of the analysis itself.
One out-of-range value on a twenty-analyte panel is expected. Two on a repeat is a finding.
Start with a baseline. A result taken before anything started converts most later ambiguity into a simple comparison, and it cannot be obtained retrospectively.
A twenty-analyte panel run on a healthy person will produce, on average, one out-of-range result purely from how reference intervals are constructed. That is arithmetic rather than pathology.
Keep the reports rather than the numbers. Units, reference intervals and methods all vary, and a bare number two years later is not comparable to anything.
Biological variation data are published per analyte and are the basis for the reference change value — the difference between two results that is larger than noise.
Decide the action for each result before you order the test.
edited 23 Oct 2025 by zeynep_arslan — clarified the distinction between purity and content
The honest position is that most people order too many analytes and too few time points, when the reverse would be more informative.
Timing matters per analyte: cortisol and testosterone are diurnal, triglycerides are postprandial, and creatinine responds to hydration and to recent training. Fixing the conditions removes most of the noise.
Research-use compounds are not approved for human use, and no panel makes that safer.
Keep the full report, not the number. You will need the units and the interval later.
The short version: a small, well-chosen panel with a baseline beats a large one without.
A sensible core for this population is a full blood count, renal function with electrolytes, liver enzymes with bilirubin, a fasting lipid panel with apolipoprotein B, HbA1c and thyroid-stimulating hormone.
The caveat is that a panel is not a diagnosis and interpreting one is a clinician's job, particularly when several values move together.
Baseline first, then a repeat under identical conditions. Everything else is secondary.
edited 21 Jan 2026 by Dr_Otto_Lindqvist — expanded the table to cover the lower concentration
Ask PeptideStack is a static archive. Posting is closed, but the norms are worth stating: answer the question that was asked, show your working, cite the trial or the certificate, and say plainly where the evidence runs out.